Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

Inclusion Criteria: * Healthy adult, 18-45 * Available for duration of study (9 months) * Written informed consent prior to any study procedures Exclusion Criteria: * Prior receipt of an investigational malaria vaccine or one containing MPL or QS-21 * Use of any investigational or non-registered drug/vaccine or planned administration of vaccine not foreseen by study protocol; each issue within 30 days preceding the first dose of study vaccine * Administration of chronic immunosuppressants * Chronic use of antibiotics * History of malaria ever, or use of malaria chemoprophylaxis within 60 days prior to vaccination * Known exposure to malaria within the past 12 months or planned travel to malarious area during the study period * Confirmed or suspected immunosuppressive or immunodeficient condition * Family history of congenital or hereditary immunodeficiency * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine * Chronic or active neurologic disease including seizures * History of splenectomy * Seropositive for hepatitis B or hepatitis C or Human Immunodeficiency Virus (HIV), or other abnormal labs such as significant anemia, elevated creatinine * Hepatomegaly, or right upper quadrant abdominal pain * Pregnant or lactating female * Chronic or active drug or alcohol use * History of severe reactions to mosquito bites * Any history of anaphylaxis to vaccinations